Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): A multicenter randomized controlled trial

被引：14
|
作者：
Koerkamp, B. Groot [1 ]
Janssen, Q. P. [1 ]
van Dam, J. L. [1 ]
Bonsing, B. A. [2 ]
Bos, H. [3 ]
Bosscha, K. P. [4 ]
Haberkorn, B. C. M. [5 ]
de Hingh, I. H. J. T. [6 ]
Karsten, T. M. [7 ]
Van der Kolk, M. B. [8 ]
Liem, M. S. L. [9 ]
Loosveld, O. J. L. [10 ]
Patijn, G. A. [11 ]
van Santvoort, H. C. M. [12 ]
de Vos-Geelen, J. [13 ]
van der Holt, B. [14 ]
Homs, M. Y. V. [15 ]
van Tienhoven, G. [16 ]
Besselink, M. G. [17 ]
Wilmink, H. W. [18 ]
机构：
[1] Erasmus MC Canc Inst, Surg, Rotterdam, Netherlands
[2] LUMC Leiden Univ Med Ctr, Surg, Leiden, Netherlands
[3] Ziekenhuis Tjongerschans, Internal Med, Heerenveen, Netherlands
[4] Jeroen Bosch Hosp, Surg, Shertogenbosch, Netherlands
[5] Maasstad Ziekenhuis, Internal Med, Rotterdam, Netherlands
[6] Catharina Hosp, Surg, Eindhoven, Netherlands
[7] OLVG Hosp, Surg, Amsterdam, Netherlands
[8] Radboud Univ Nijmegen, Surg, Med Ctr, Nijmegen, Netherlands
[9] Med Spectrum Twente, Surg, Enschede, Netherlands
[10] Amphia Ziekenhuis Locat Molengracht, Dept Med Oncol, Breda, Netherlands
[11] Isala Hosp, Surg, Zwolle, Netherlands
[12] UMC Univ Med Ctr Utrecht, Surg, Utrecht, Netherlands
[13] Maastricht Univ Med Ctr MUMC, Dept Med Oncol, Maastricht, Netherlands
[14] Erasmus MC Canc Inst, Hematol, Rotterdam, Netherlands
[15] Erasmus MC Canc Inst, Med Oncol, Rotterdam, Netherlands
[16] Univ Amsterdam, Radiat Oncol, Amsterdam UMC, Amsterdam, Netherlands
[17] Univ Amsterdam, Surg, Amsterdam UMC, Amsterdam, Netherlands
[18] Univ Amsterdam, Med Oncol, Amsterdam UMC, Amsterdam, Netherlands
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.084
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA83
引用
收藏
页码：S1323 / S1323
页数：1
相关论文
共 50 条
  • [31] Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial
    Versteijne, Eva
    Suker, Mustafa
    Groothuis, Karin
    Akkermans-Vogelaar, Janine M.
    Besselink, Marc G.
    Bonsing, Bert A.
    Buijsen, Jeroen
    Busch, Olivier R.
    Creemers, Geert-Jan M.
    van Dam, Ronald M.
    Eskens, Ferry A. L. M.
    Festen, Sebastiaan
    de Groot, Jan Willem B.
    Koerkamp, Bas Groot
    de Hingh, Ignace H.
    Homs, Marjolein Y., V
    van Hooft, Jeanin E.
    Kerver, Emile D.
    Luelmo, Saskia A. C.
    Neelis, Karen J.
    Nuyttens, Joost
    Paardekooper, Gabriel M. R. M.
    Patijn, Gijs A.
    van der Sangen, Maurice J. C.
    de Vos-Geelen, Judith
    Wilmink, Johanna W.
    Zwinderman, Aeilko H.
    Punt, Cornelis J.
    van Eijck, Casper H.
    van Tienhoven, Geertjan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (16) : 1763 - +
  • [32] Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: The NEPAFOX trial.
    Al-Batran, Salah-Eddin
    Reichart, Alexander
    Bankstahl, Ulli Simone
    Pauligk, Claudia
    Kraus, Thomas Werner
    Bechstein, Wolf Otto
    Trojan, Jorg
    Behrend, Matthias
    Potenberg, Jochem
    Homann, Nils
    Venerito, Marino
    Bohle, Wolfram
    Varvenne, Michael
    Bolling, Claus
    Behringer, Dirk M.
    Kratz-Alber, Karsten
    Siegler, Gabriele Margareta
    Hozaeel, Wael
    Goetze, Thorsten Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [33] FOLFIRINOX versus Gemcitabine/nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Adenocarcinoma: A Propensity Matched Analysis
    Dhir, M.
    Zenati, M. S.
    Hamad, A.
    Singhi, A. D.
    Bahary, N.
    Hogg, M.
    Zeh, H.
    Zureikat, A.
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : S8 - S8
  • [34] Survival benefit of neoadjuvant FOLFIRINOX for patients with borderline resectable pancreatic cancer
    Waugh, Evelyn
    Glinka, Juan
    Breadner, Daniel
    Liu, Rachel
    Tang, Ephraim
    Allen, Laura
    Welch, Stephen
    Leslie, Ken
    Skaro, Anton
    ANNALS OF HEPATO-BILIARY-PANCREATIC SURGERY, 2024, 28 (02) : 229 - 237
  • [35] Preoperative Gemcitabine-based Chemoradiation Therapy for Resectable and Borderline Resectable Pancreatic Cancer
    Ravikumar, Reena
    Fusai, Giuseppe
    ANNALS OF SURGERY, 2015, 262 (06) : E103 - E103
  • [36] Preoperative Gemcitabine-Based Chemoradiation Therapy for Resectable and Borderline Resectable Pancreatic Cancer
    Takahashi, Hidenori
    Ohigashi, Hiroaki
    Gotoh, Kunihito
    Marubashi, Shigeru
    Yamada, Terumasa
    Murata, Masayuki
    Ioka, Tatsuya
    Uehara, Hiroyuki
    Yano, Masahiko
    Ishikawa, Osamu
    ANNALS OF SURGERY, 2013, 258 (06) : 1040 - 1050
  • [37] Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX
    Choi, Yoo Jin
    Byun, Yoonhyeong
    Kang, Jae Seung
    Kim, Hyeong Seok
    Han, Youngmin
    Kim, Hongbeom
    Kwon, Wooil
    Oh, Do-Youn
    Paik, Woo Hyun
    Lee, Sang Hyub
    Ryu, Ji Kon
    Kim, Yong-Tae
    Lee, Kyungbun
    Kim, Haeryoung
    Chie, Eui Kyu
    Jang, Jin-Young
    GUT AND LIVER, 2021, 15 (03) : 466 - 475
  • [38] ASO Visual Abstract: Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer-The Randomized Multicenter Phase II NEPAFOX Trial
    Goetze, Thorsten O.
    Reichart, Alexander
    Bankstahl, Ulli S.
    Pauligk, Claudia
    Loose, Maria
    Kraus, Thomas W.
    Elshafei, Moustafa
    Bechstein, Wolf O.
    Trojan, Joerg
    Behrend, Matthias
    Homann, Nils
    Venerito, Marino
    Bohle, Wolfram
    Varvenne, Michael
    Bolling, Claus
    Behringer, Dirk M.
    Kratz-Albers, Karsten
    Siegler, Gabriele M.
    Hozaeel, Wael
    Al-Batran, Salah-Eddin
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (6) : 4121 - 4122
  • [39] Neoadjuvant Chemoradiotherapy improves oncological results in resectable and borderline resectable Pancreatic Carcinomas, but not Overall Survival in resectable ones Results of the Dutch PREOPANC Study
    Hermann, Robert Michael
    Christiansen, Hans
    STRAHLENTHERAPIE UND ONKOLOGIE, 2021, 197 (01) : 85 - 88
  • [40] Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial
    Eva Versteijne
    Casper H. J. van Eijck
    Cornelis J. A. Punt
    Mustafa Suker
    Aeilko H. Zwinderman
    Miriam A. C. Dohmen
    Karin B. C. Groothuis
    Oliver R. C. Busch
    Marc G. H. Besselink
    Ignace H. J. T. de Hingh
    Albert J. ten Tije
    Gijs A. Patijn
    Bert A. Bonsing
    Judith de Vos-Geelen
    Joost M. Klaase
    Sebastiaan Festen
    Djamila Boerma
    Joris I. Erdmann
    I. Quintus. Molenaar
    Erwin van der Harst
    Marion B. van der Kolk
    Coen R. N. Rasch
    Geertjan van Tienhoven
    Trials, 17
12345